BioCryst Pharmaceuticals, Inc.
BCRXNext catalyst
navenibart
Hereditary Angioedema (HAE)
Get an email about BCRX's next catalysts
Track BioCryst Pharmaceuticals (BCRX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
navenibart Phase 3 Est. Readout
Primary completion for navenibart trial (NCT06842823) in Hereditary Angioedema (HAE)
SourceMarket Overview
Stock performance and key metrics
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
WebsiteOseltamivir
Influenza
BCX4161
Hereditary Angioedema
Peramivir
Influenza
Berotralstat
Hereditary Angioedema
BCX7353 capsules
Hereditary Angioedema, HAE
BCX7353
Hereditary Angioedema (HAE)
navenibart
Hereditary Angioedema (HAE)
BCX-1777
Leukemia, Lymphocytic
forodesine hydrochloride (BCX-1777)
Leukemia, T-Cell
Ulodesine (BCX4208)
Gout
BCX9930
Paroxysmal Nocturnal Hemoglobinuria
Allopurinol
Gout
STAR-0215
Hereditary Angioedema
BCX4208
Gout
ulodesine
Gout
Forodesine
Cutaneous T-cell Lymphoma (CTCL),
forodesine HCl
Chronic Lymphocytic Leukemia (CLL)
forodesine hydrochloride
Lymphoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Oseltamivir | Phase 3 | Influenza | - | - |
BCX4161 | Phase 3 | Hereditary Angioedema | - | - |
Peramivir | Phase 3 | Influenza | - | - |
Berotralstat | Phase 3 | Hereditary Angioedema | - | - |
BCX7353 capsules | Phase 3 | Hereditary Angioedema, HAE | - | - |
BCX7353 | Phase 3 | Hereditary Angioedema (HAE) | - | - |
navenibart | Phase 3 | Hereditary Angioedema (HAE) | - | - |
BCX-1777 | Phase 2 | Leukemia, Lymphocytic | - | - |
forodesine hydrochloride (BCX-1777) | Phase 2 | Leukemia, T-Cell | - | - |
Ulodesine (BCX4208) | Phase 2 | Gout | - | - |
BCX9930 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Allopurinol | Phase 2 | Gout | - | - |
STAR-0215 | Phase 2 | Hereditary Angioedema | - | - |
BCX4208 | Phase 2 | Gout | - | - |
ulodesine | Phase 2 | Gout | - | - |
Forodesine | Phase 2 | Cutaneous T-cell Lymphoma (CTCL), | - | - |
forodesine HCl | Phase 2 | Chronic Lymphocytic Leukemia (CLL) | - | - |
forodesine hydrochloride | Phase 2 | Lymphoma | - | - |
Frequently asked questions
What is in BioCryst Pharmaceuticals, Inc.'s drug pipeline?β
CatalystAlert tracks 18 drug candidates in BioCryst Pharmaceuticals, Inc.'s (BCRX) pipeline across Phase 3, Phase 2. Its lead program is navenibart (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BioCryst Pharmaceuticals, Inc.'s next FDA catalyst?β
BioCryst Pharmaceuticals, Inc.'s (BCRX) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BCRX biotech catalysts?β
Add BCRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BioCryst Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
